Stock Price Quote

BAFNA PHARMACEUTICALS LTD.

NSE : BAFNAPHBSE : 532989ISIN CODE : INE878I01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE91.000 (0 %)
PREV CLOSE ( ) 91.00
OPEN PRICE ( ) 91.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 280
TODAY'S LOW / HIGH ( )91.00 92.00
52 WK LOW / HIGH ( )78.51 125.55
NSE90.00-1.3 (-1.42 %)
PREV CLOSE( ) 91.30
OPEN PRICE ( ) 93.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5498
TODAY'S LOW / HIGH( ) 90.00 93.95
52 WK LOW / HIGH ( )77.05 124.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1995
Management Info
Shanmugam Hemalatha - Chairman - Managing Director
Registered Office

Address Bafna Towers,New No 68, Old No.299,Thambu Chetty Street,
Chennai,
Tamil Nadu-600001

Phone 044- 25267517 / 25270992 / 42677555

Email info@bafnapharma.com

Website www.bafnapharma.com

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE, MCX

NEWS

02Feb Bafna Pharmaceuticals informs about bo
Bafna Pharmaceuticals has informed that meeting of board of directors of..
08Dec Announcement under Regulation 30 (LOD
we hereby inform you that due to torrential rains/impact of "Michaung" c..
23Sep Bafna Pharmaceuticals informs about re
Bafna Pharmaceuticals has informed that Kamlesh Kumar Babulal (DIN: 0121..
13Jul Bafna Pharmaceuticals informs about ce
Pursuant to Regulation 74(5) of the SEBI (Depository & Participants)..
04Apr Bafna Pharmaceuticals informs about bo
Bafna Pharmaceuticals has informed that a meeting of the Board of Direct..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-29.43113.4
Gross Profit -29.43 116.18
Operating Profit -10.96189.9
Net Sales 284.421153.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2145.85 (4.89%)
M.Cap ( in Cr)1325.71
Neuland Laboratories (BSE)
peergroup  7118.95 (0.84%)
M.Cap ( in Cr)9133.53
Alembic Pharma (BSE)
peergroup  1047.25 (4.19%)
M.Cap ( in Cr)20585.07
Glaxosmithkline Phar (BSE)
peergroup  2295.10 (1.75%)
M.Cap ( in Cr)38880.38
Glenmark Pharma (BSE)
peergroup  893.90 (3.64%)
M.Cap ( in Cr)25224.80

Shareholding Pattern

PROMOTERS 88.43%
NON-INSTITUTION 11.57%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Bafna Pharmaceuticals Ltd.

Bafna Pharmaceuticals Ltd. was incorporated in the year 1995. Its today's share price is 91. Its current market capitalisation stands at Rs 215.27 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1153.5 Cr and Total Income of Rs.1186.23 Cr. The company's management includes Krishna Yeachuri, Upendar Mekala Reddy, Vinayak Dinesh Dendukuri, Vishnu Vasudeva Kuppa, Shanmugam Hemalatha, R Chitra, B Kamlesh Kumar, P K Sundaresan, Akila Chintalapati Raju.

It is listed on the BSE with a BSE Code of 532989 , NSE with an NSE Symbol of BAFNAPH and ISIN of INE878I01022. It's Registered office is at Bafna Towers,New No 68, Old No.299,Thambu Chetty StreetChennai-600001, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Abhay Jain & Co, Brahmayya & Co, R Sathyanarayanan & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.